Research Alliance IV completes $75 million IPO of 7.5 million Class A shares
Research Alliance Corporation IV, a blank check company focused on healthcare, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The IPO and a $2.75 million private placement to the sponsor funded a trust account of $75 million for public shareholders. The filing says the company must complete an initial business combination within 24 months of the IPO closing, or liquidate.
Key points
- Closed IPO of 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses.
- Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares at $10.00 each, for total proceeds of $2,750,000.
- $75,000,000 of net proceeds and private placement funds, including a $2,250,000 underwriter deferred commission, were deposited in a trust account with Continental Stock Transfer & Trust Company as trustee.
- Alan Musso and John Maslowski were appointed to the board on July 10, 2026, and each received 30,000 Class B ordinary shares from the sponsor as compensation.
The filing
Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.